Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Denali Therapeutics (DNLI) Cash from Operations: 2017-2025

Historic Cash from Operations for Denali Therapeutics (DNLI) over the last 9 years, with Sep 2025 value amounting to -$107.3 million.

  • Denali Therapeutics' Cash from Operations fell 81.43% to -$107.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$397.8 million, marking a year-over-year decrease of 9.69%. This contributed to the annual value of -$347.7 million for FY2024, which is 2.88% up from last year.
  • Latest data reveals that Denali Therapeutics reported Cash from Operations of -$107.3 million as of Q3 2025, which was down 42.50% from -$75.3 million recorded in Q2 2025.
  • Over the past 5 years, Denali Therapeutics' Cash from Operations peaked at -$41.4 million during Q3 2021, and registered a low of -$131.5 million during Q1 2025.
  • For the 3-year period, Denali Therapeutics' Cash from Operations averaged around -$92.7 million, with its median value being -$91.2 million (2024).
  • Per our database at Business Quant, Denali Therapeutics' Cash from Operations plummeted by 48,279.07% in 2021 and then skyrocketed by 32.31% in 2024.
  • Over the past 5 years, Denali Therapeutics' Cash from Operations (Quarterly) stood at -$65.5 million in 2021, then dropped by 10.95% to -$72.7 million in 2022, then plummeted by 35.77% to -$98.7 million in 2023, then climbed by 15.15% to -$83.7 million in 2024, then plummeted by 81.43% to -$107.3 million in 2025.
  • Its Cash from Operations stands at -$107.3 million for Q3 2025, versus -$75.3 million for Q2 2025 and -$131.5 million for Q1 2025.